Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Apr 9, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-03-30

Reporting Person: DeLong Mark Jeffrey (Senior Vice President)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8698	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$44.90	2031-01-27	Common Stock (30000)		Direct
Stock Option (Right to Buy)	$44.33	2030-02-09	Common Stock (18750)		Direct
Stock Option (Right to Buy)	$15.52	2028-02-04	Common Stock (50000)		Direct
Stock Option (Right to Buy)	$13.85	2029-02-27	Common Stock (30000)		Direct

Footnotes

F1: This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.